Cargando…

PD‐L1 blockade enhances response of pancreatic ductal adenocarcinoma to radiotherapy

Pancreatic ductal adenocarcinoma (PDAC) is considered a non‐immunogenic tumor, and immune checkpoint inhibitor monotherapy lacks efficacy in this disease. Radiotherapy (RT) can stimulate the immune system. Here, we show that treatment of KPC and Pan02 murine PDAC cells with RT and gemcitabine upregu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Azad, Abul, Yin Lim, Su, D'Costa, Zenobia, Jones, Keaton, Diana, Angela, Sansom, Owen J, Kruger, Philipp, Liu, Stanley, McKenna, W Gillies, Dushek, Omer, Muschel, Ruth J, Fokas, Emmanouil
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2016
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5286375/ https://www.ncbi.nlm.nih.gov/pubmed/27932443 http://dx.doi.org/10.15252/emmm.201606674

Ejemplares similares

Prognostic value, localization and correlation of PD-1/PD-L1, CD8 and FOXP3 with the desmoplastic stroma in pancreatic ductal adenocarcinoma
por: Diana, Angela, et al.
Publicado: (2016)

Prognostic role and correlation of CA9, CD31, CD68 and CD20 with the desmoplastic stroma in pancreatic ductal adenocarcinoma
por: Diana, Angela, et al.
Publicado: (2016)

The prognostic role of desmoplastic stroma in pancreatic ductal adenocarcinoma
por: Wang, Lai Mun, et al.
Publicado: (2015)

An efficient and robust MRI-guided radiotherapy planning approach for targeting abdominal organs and tumours in the mouse
por: Kersemans, Veerle, et al.
Publicado: (2017)

NVP-BEZ235 and NVP-BGT226, dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitors, enhance tumor and endothelial cell radiosensitivity
por: Fokas, Emmanouil, et al.
Publicado: (2012)

Impacts of combining anti-PD-L1 immunotherapy and radiotherapy on the tumour immune microenvironment in a murine prostate cancer model
por: Philippou, Yiannis, et al.
Publicado: (2020)

The anti-malarial atovaquone increases radiosensitivity by alleviating tumour hypoxia
por: Ashton, Thomas M., et al.
Publicado: (2016)

Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation
por: Fokas, E, et al.
Publicado: (2012)

Radiotherapy induces responsiveness of a resistant mammary carcinoma to PD-1 blockade
por: Diamond, Julie, et al.
Publicado: (2014)

Combination PD-1 and PD-L1 Blockade Promotes Durable Neoantigen-Specific T Cell-Mediated Immunity in Pancreatic Ductal Adenocarcinoma
por: Burrack, Adam L., et al.
Publicado: (2019)

Histone deacetylase 4 interacts with 53BP1 to mediate the DNA damage response
por: Kao, Gary D., et al.
Publicado: (2003)

Radiation combined with macrophage depletion promotes adaptive immunity and potentiates checkpoint blockade
por: Jones, Keaton I, et al.
Publicado: (2018)

Blockade of the BAK Hydrophobic Groove by Inhibitory Phosphorylation Regulates Commitment to Apoptosis
por: Azad, Abul, et al.
Publicado: (2012)

Quantitative contributions of TNF receptor superfamily members to CD8(+) T‐cell responses
por: Nguyen, John, et al.
Publicado: (2021)

Image-guided radiotherapy in an orthotopic mouse model of rectal cancer
por: Nicolas, Adele M., et al.
Publicado: (2022)

Blockade of PD-1/PD-L1 Promotes Adoptive T-Cell Immunotherapy in a Tolerogenic Environment
por: Blake, Stephen J. P., et al.
Publicado: (2015)

Elementary Steps in T Cell Receptor Triggering
por: Dushek, Omer
Publicado: (2012)

Tissue-Resident Memory T Cells in Pancreatic Ductal Adenocarcinoma Coexpress PD-1 and TIGIT and Functional Inhibition Is Reversible by Dual Antibody Blockade
por: Pearce, Hayden, et al.
Publicado: (2023)

An update on immunotherapy with PD-1 and PD-L1 blockade
por: Koh, Sung Ae
Publicado: (2021)

Nanoparticle-enhanced radiotherapy synergizes with PD-L1 blockade to limit post-surgical cancer recurrence and metastasis
por: Guan, Xin, et al.
Publicado: (2022)

The Therapeutic Potential of Imidazole or Quinone-Based Compounds as Radiosensitisers in Combination with Radiotherapy for the Treatment of Head and Neck Squamous Cell Carcinoma
por: Azad, Abul, et al.
Publicado: (2022)

Near Complete Pathologic Response to PD-1 Inhibitor and Radiotherapy in a Patient with Locally Advanced Pancreatic Ductal Adenocarcinoma
por: McCarthy, Patrick M, et al.
Publicado: (2021)

Tumor Suppressor Protein p53 and Inhibitor of Apoptosis Proteins in Colorectal Cancer—A Promising Signaling Network for Therapeutic Interventions
por: Güllülü, Ömer, et al.
Publicado: (2021)

Human Cancer Immunotherapy with PD-1/PD-L1 Blockade
por: Zheng, Peilin, et al.
Publicado: (2015)

Genetic biomarkers for PD-1/PD-L1 blockade therapy
por: Kataoka, Keisuke, et al.
Publicado: (2016)

Potential Biomarkers for the Efficacy of PD-1-PD-L Blockade in Cancer
por: Grecea, Miruna, et al.
Publicado: (2021)

Management of Thyrotoxicosis Induced by PD1 or PD-L1 Blockade
por: Brancatella, Alessandro, et al.
Publicado: (2021)

Management of Thyrotoxicosis Induced by PD1 or PD-L1 Blockade
por: Brancatella, Alessandro, et al.
Publicado: (2021)

Regulation of O(2) consumption by the PI3K and mTOR pathways contributes to tumor hypoxia
por: Kelly, Catherine J., et al.
Publicado: (2014)

Application of PD-1 Blockade in Cancer Immunotherapy
por: Wu, Xiaomo, et al.
Publicado: (2019)

PD-1 Blockade in Anaplastic Thyroid Carcinoma
por: Capdevila, Jaume, et al.
Publicado: (2020)

Biomarkers of response to PD-1 pathway blockade
por: Li, Hanxiao, et al.
Publicado: (2022)

Inflammatory Cytokines and Radiotherapy in Pancreatic Ductal Adenocarcinoma
por: Ng, Sylvia S. W., et al.
Publicado: (2022)

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
por: Bai, Jie, et al.
Publicado: (2017)

The anti-tumor immune response generated by radiation therapy may be limited by tumor cell adaptive resistance and can be circumvented by PD-L1 blockade
por: Dovedi, Simon, et al.
Publicado: (2014)

PD-1/PD-L1 blockade in cancer treatment: perspectives and issues
por: Hamanishi, Junzo, et al.
Publicado: (2016)

Oncolytic virus and PD-1/PD-L1 blockade combination therapy
por: Chen, Chun-Yu, et al.
Publicado: (2018)

Drug response to PD-1/PD-L1 blockade: based on biomarkers
por: Chen, Qi, et al.
Publicado: (2018)

Efficacy of PD-1/PD-L1 blockade monotherapy in clinical trials
por: Zhao, Bin, et al.
Publicado: (2020)

Is There a Place for PD-1-PD-L Blockade in Acute Myeloid Leukemia?
por: Jimbu, Laura, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_v1kph5e64r9hif4j08j10d2mom